PMC:6562565 / 48343-48484 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/6562565","sourcedb":"PMC","sourceid":"6562565","source_url":"https://www.ncbi.nlm.nih.gov/pmc/6562565","text":"NCT03742349 NIR178 Ib ➣ In combination with spartalizumab (anti-PD-1) and LAG525(anti-LAG3) Triple-negative Breast Cancer Novartis 2018","divisions":[{"label":"td","span":{"begin":0,"end":11}},{"label":"td","span":{"begin":13,"end":19}},{"label":"td","span":{"begin":21,"end":23}},{"label":"td","span":{"begin":25,"end":94}},{"label":"p","span":{"begin":25,"end":94}},{"label":"td","span":{"begin":96,"end":125}},{"label":"td","span":{"begin":127,"end":135}}],"tracks":[]}